Insights


The Future of RET Inhibitors in Non-Small Cell Lung and Thyroid Cancer

October 18th 2019

Navigating the Complexities of HCC

September 10th 2019

Inside the Clinic: Acute Graft-versus-Host Disease

August 2nd 2019

Key Considerations for Detecting and Targeting BRAF Mutations

July 31st 2019

TRK Inhibitors: Evolution of a Tumor-Agnostic Treatment Approach

July 30th 2019

Whats Next? Sequencing Later-Line Therapies in Metastatic CRC

July 15th 2019

Advances in Treatment for ALK-Positive NSCLC

July 12th 2019

Frontline Therapy In Follicular Lymphoma

July 9th 2019

AFP as a Prognostic and Predictive Marker in HCC

June 17th 2019

Inside the Clinic: Global Insights: Multidisciplinary Care of Stage III NSCLC

May 2nd 2019

Expanding Role of PARP Inhibitors in Advanced Ovarian Cancer

April 29th 2019

Advances in BRAF-Targeted Therapy for Metastatic Melanoma

March 28th 2019

ADT and the Risk of Major Adverse Cardiovascular Events

March 25th 2019

Evolving Treatment Landscape of BTK Inhibitors in B-Cell Malignancies

March 4th 2019

Emerging Approaches: Pancreatic Cancer Systemic Therapy

February 20th 2019

Treating Mantle Cell Lymphoma: Role of BTK Inhibition

January 18th 2019

Expert Perspective on the Treatment of Multiple Myeloma

January 17th 2019

Novel “Tissue-Agnostic” Targeted Treatment

January 14th 2019

Novel Therapeutic Agents for Acute Myeloid and Chronic Lymphocytic Leukemia

January 8th 2019

Advances in the Treatment of Relapsed/Refractory Myeloma

November 22nd 2018